IP Library Granted Patent US 11,708,461
Granted Patent B2
US 11,708,461 · App. 17/129,366 · Granted Jul 25, 2023

Method for preparing acylated crosslinked glycosaminoglycans

Inventors: Johan Olsson (Bromma, SE); Craig Steven Harris (Biot, FR)
Assignee: Galderma Holding SA
C08J3/075A61K8/042A61K8/73A61K8/735A61K9/0019A61Q19/00C07C209/62C07C213/00C07C269/06C07F7/083C08B37/0063C08B37/0069C08B37/0072C08J3/24C08J7/14C08K5/09C08L5/00C08L5/08C07C2603/18C08J2305/00C08J2305/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,708,461
App. No.
17/129,366
Granted
Jul 25, 2023
Kind
B2
Abstract

A method of preparing a hydrogel product including crosslinked glycosaminoglycan molecules, said method including: i) providing a glycosaminoglycan crosslinked by amide bonds, wherein the crosslinked glycosaminoglycans include residual amine groups; and ii) acylating residual amine groups of the crosslinked glycosaminoglycans provided in i) to form acylated crosslinked glycosaminoglycans.

Claims (34)

1. A hydrogel comprising acylated crosslinked glycosaminoglycans (GAGs), wherein the crosslinked GAGs comprise:

an at least partially deacetylated GAG comprising free amine groups; and

a second GAG,

wherein the at least partially deacetylated GAG is crosslinked to the second GAG by amide bonds formed between 2′-amino groups of the at least partially deacetylated GAG and activated carboxyl groups of the second GAG; and

wherein the hydrogel has residual free amine groups and a degree of acetylation of at least 95%.

2. The hydrogel according to claim 1 , wherein the crosslinked GAGs are prepared by a method comprising:

(a) obtaining a solution comprising the at least partially deacetylated GAG, and the second GAG;

(b) activating carboxyl groups on the at least partially deacetylated GAG and/or the second GAG with a coupling agent, forming activated GAGs;

(c) crosslinking the activated GAGs via their activated carboxyl groups using 2′-amino groups of the at least partially deacetylated GAGs, forming the amide bond-crosslinked GAGs.

3. The hydrogel according to claim 2 , wherein the at least partially deacetylated GAG is selected from the group consisting of deacetylated hyaluronic acid, deacetylated chondroitin, and deacetylated chondroitin sulfate, and mixtures thereof.

4. The hydrogel according to claim 2 , wherein the at least partially deacetylated GAG is deacetylated hyaluronic acid.

5. The hydrogel according to claim 2 , wherein the at least partially deacetylated GAG has a degree of acetylation of 95% or less, and a weight average molecular weight of 0.1 MDa or more.

6. The hydrogel according to claim 2 , wherein the at least partially deacetylated glycosaminoglycan is prepared by:

(a) allowing a GAG comprising N-acetyl groups to react with hydroxylamine (NH 2 OH), or a salt thereof, at a temperature of 100° C. or less for 2-200 hours to form an at least partially deacetylated GAG, and

(b) recovering the at least partially deacetylated GAG.

7. The hydrogel according to claim 2 , wherein the second GAG is selected from the group consisting of hyaluronic acid, chondroitin, and chondroitin sulfate, and mixtures thereof.

8. The hydrogel according to claim 2 , wherein the second GAG is hyaluronic acid.

9. The hydrogel according to claim 2 , wherein the coupling agent is a peptide coupling reagent.

10. The hydrogel according to claim 2 , wherein the coupling reagent is DMTMM.

11. The hydrogel according to claim 2 , wherein the method of preparing the crosslinked GAGs further comprises acetylating residual free amine groups of the crosslinked GAGs to form acetylated crosslinked GAGs.

12. The hydrogel according to claim 2 , wherein the method of preparing the crosslinked GAGs further comprises subjecting the crosslinked GAGs to an alkaline solution to hydrolyze ester crosslinks formed as byproducts during the amide crosslinking.

13. The hydrogel according to claim 12 , wherein the alkaline solution comprises sodium hydroxide or potassium hydroxide.

14. The hydrogel according to claim 13 , wherein the crosslinked GAGs are subjected to the sodium hydroxide solution at a pH between 12-14 for 0.5 to 4 hours.

15. The hydrogel according to claim 1 , wherein the hydrogel is in a solid dry form.

16. The hydrogel according to claim 1 , wherein the hydrogel is precipitated in an alcohol.

17. A composition comprising:

the hydrogel according to claim 1 ; and

water.

18. The composition according to claim 17 , wherein the composition is formulated as an injectable composition.

19. The composition according to claim 17 , wherein the hydrogel is suspended in saline solution.

20. The composition according to claim 19 , wherein the pH of the saline solution is 7.4.

21. The hydrogel according to claim 1 , wherein the crosslinked GAGs are substantially free of ester crosslinks.

22. The hydrogel according to claim 1 , wherein the crosslinked GAGs comprise two different GAGs selected from hyaluronic acid, chondroitin, chondroitin sulphate, heparin sulphate, heparosan, heparin, dermatan sulphate, and keratin sulphate.

23. The hydrogel according to claim 1 , wherein the second GAG is non-deacetylated.

Assignments (5)
CHANGE OF ADDRESS Recorded Jun 27, 2022
From: GALDERMA HOLDING SA
To: GALDERMA HOLDING SA
Reel/Frame 061113/0710 →
CORRECTIVE ASSIGNMENT TO CORRECT THE THE ASSIGNEES ADDRESS PREVIOUSLY RECORDED AT REEL: 057652 FRAME: 0859. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Dec 13, 2021
From: GALDERMA S.A.
To: NESTLÉ SKIN HEALTH S.A.
Reel/Frame 058495/0582 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2021
From: OLSSON, JOHAN; HARRIS, CRAIG STEVEN
To: GALDERMA S.A.
Reel/Frame 057884/0528 →
CHANGE OF NAME Recorded Sep 29, 2021
From: NESTLÉ SKIN HEALTH S.A.
To: GALDERMA HOLDING SA
Reel/Frame 057631/0589 →
AMENDMENT TO ASSET TRANSFER AGREEMENT Recorded Sep 29, 2021
From: GALDERMA S.A.
To: NESTLÉ SKIN HEALTH S.A.
Reel/Frame 057652/0859 →